logo conference-reports

Hasil Konferensi

Educational funding by logo MSD Oncology

ASCO-GI 2020 – Unresectable HCC: atezolizumab plus bevacizumab tops sorafenib in patient-reported outcomes

Quality of life analysis of the IMbrave150 trial.